Nevro (NYSE:NVRO) Announces Earnings Results, Beats Estimates By $0.15 EPS

Nevro (NYSE:NVRO) announced its quarterly earnings results on Tuesday. The medical equipment provider reported ($0.64) EPS for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.15, Zacks reports. Nevro had a negative net margin of 16.54% and a negative return on equity of 23.52%. The business had revenue of $105.55 million for the quarter, compared to analyst estimates of $102.61 million.

Nevro Trading Up 1.0 %

NVRO opened at $5.79 on Thursday. Nevro has a twelve month low of $3.17 and a twelve month high of $15.98. The company has a quick ratio of 3.76, a current ratio of 5.02 and a debt-to-equity ratio of 0.67. The company has a fifty day moving average of $4.89 and a 200-day moving average of $4.94. The stock has a market cap of $216.78 million, a PE ratio of -3.06 and a beta of 0.94.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. StockNews.com assumed coverage on shares of Nevro in a research report on Thursday. They set a “hold” rating on the stock. Jefferies Financial Group upgraded shares of Nevro from an “underperform” rating to a “hold” rating and increased their price target for the stock from $4.50 to $5.85 in a research report on Monday, February 10th. Truist Financial reduced their price target on shares of Nevro from $7.00 to $4.70 and set a “hold” rating on the stock in a research report on Wednesday, December 18th. Royal Bank of Canada reiterated a “sector perform” rating and set a $7.00 price target on shares of Nevro in a research report on Tuesday, November 12th. Finally, Morgan Stanley lowered shares of Nevro from an “equal weight” rating to an “underweight” rating and reduced their price target for the stock from $9.00 to $4.00 in a research report on Monday, December 2nd. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Nevro presently has an average rating of “Hold” and an average price target of $6.43.

About Nevro

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.